Xcorporeal, Inc. it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. The platforms lead to three initial products: portable artificial kidney (PAK), for attended care renal replacement therapy (RRT), for patients suffering from acute renal failure (ARF); a PAK for home hemodialysis for patients suffering from end stage renal disease (ESRD), and a wearable artificial kidney (WAK) for continuous ambulatory hemodialysis for treatment of ESRD. The PAK for the attended care market is a portable, multifunctional renal replacement device that would offer therapy for those patients suffering from ARF, causing a rapid decline in kidney function. The PAK for the home hemodialysis market is a device for patients suffering from ESRD, in whom the kidneys have ceased to function. The WAK is a device for the chronic treatment of ESRD.
Revenue (Most Recent Fiscal Year) | -- |
Net Income (Most Recent Fiscal Year) | -- |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -- |
Return on Assets (Trailing 12 Months) | -- |
Current Ratio (Most Recent Fiscal Quarter) | -- |
Quick Ratio (Most Recent Fiscal Quarter) | -- |
Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | -- |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | NYSEMKT |
Sector | Healthcare |
Industry | Medical Devices |
Common Shares Outstanding | -- |
Free Float | -- |
Market Capitalization | -- |
Average Volume (Last 20 Days) | -- |
Beta (Past 60 Months) | -- |
Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |